Request Trial
rabbit-nose
28 February 2014Americas

Combating cancer: Apexigen and rabbit antibodies

There’s no shortage of drugs formulated with antibodies derived from people or from mice. But California-based Apexigen has turned elsewhere, developing treatments with antibodies derived from rabbits.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Novartis takes aim at Tafinlar generic in latest suit
9 February 2026   The Swiss pharma giant moves to protect patents on its billion-dollar cancer therapy following an ANDA filing by a Canadian generics manufacturer.
Americas
Semaglutide patent battle heats up with new blow for Novo in India
6 February 2026   A Delhi High Court ruling signals more bad news for the Danish pharma giant in the same week that it lost nearly $50 billion in value.
Americas
LSPN Awards USA returns for second year—with new categories
3 February 2026   Nominations are open for the Life Sciences Patent Network's 2026 awards in Boston, including six new categories and winners selected by leading industry experts.


Editor's picks

AstraZeneca partners with Chinese firm ahead of next obesity race
Asia
AstraZeneca partners with Chinese firm ahead of next obesity race
5 February 2026

Editor's picks

Asia
AstraZeneca partners with Chinese firm ahead of next obesity race
5 February 2026
Europe
Final call: Who are the world’s best in-house counsel?
16 January 2026
Americas
Bayer enters COVID-19 vaccine row with three suits against major drugmakers
8 January 2026
Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025
Europe
Abbott appeals ‘baffling’ decision in glucose monitoring device feud
16 December 2025
Americas
Teva scrubs 200-plus Orange Book patents after FTC turns the screw
11 December 2025

More features

Novartis takes aim at Tafinlar generic in latest suit
Semaglutide patent battle heats up with new blow for Novo in India
Wilson Sonsini senior counsel moves to a rival firm
INTA: ‘Davos of IP’ will take London meeting to a ‘different level’
Nine-partner litigation team leaves Winston & Strawn
LSPN Awards USA returns for second year—with new categories
Crowell adds tech partner with in-house and private practice expertise
Winston & Strawn and Taylor Wessing UK seal ‘powerhouse’ merger